EDAP TMS S.A. (EDAP) Reports Q3 EPS of EUR0.19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
EDAP Reports Third Quarter 2015 Financial Results and Operational Update
November 18, 2015 5:45 PM ESTObtained FDA clearance for Ablatherm® HIFU in November Received first four U.S. orders for Ablatherm Record nine-month net sales of 20.5 million HIFU treatment-driven revenue increased 41% year-over-year Strong backlog for both lithotripsy and HIFU divisions entering Q4 First Focal One® Device sold in South America
LYON, France, Nov. 18, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced financial results for the third quarter ended September 30, 2015 and provided an update on recent strategic and operational highlights.
Marc... More
